JP2025510594A - Ｂｔｎ１ａ１結合タンパク質及びその使用方法 - Google Patents

Ｂｔｎ１ａ１結合タンパク質及びその使用方法 Download PDF

Info

Publication number
JP2025510594A
JP2025510594A JP2024553845A JP2024553845A JP2025510594A JP 2025510594 A JP2025510594 A JP 2025510594A JP 2024553845 A JP2024553845 A JP 2024553845A JP 2024553845 A JP2024553845 A JP 2024553845A JP 2025510594 A JP2025510594 A JP 2025510594A
Authority
JP
Japan
Prior art keywords
seq
antibody
cdr1
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510594A5 (enExample
Inventor
エス． ヨー ステファン
Original Assignee
ストキューブ アンド シーオー．， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ストキューブ アンド シーオー．， インコーポレイテッド filed Critical ストキューブ アンド シーオー．， インコーポレイテッド
Publication of JP2025510594A publication Critical patent/JP2025510594A/ja
Publication of JP2025510594A5 publication Critical patent/JP2025510594A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
JP2024553845A 2022-03-16 2023-03-15 Ｂｔｎ１ａ１結合タンパク質及びその使用方法 Pending JP2025510594A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320646P 2022-03-16 2022-03-16
US63/320,646 2022-03-16
PCT/US2023/064478 WO2023178208A2 (en) 2022-03-16 2023-03-15 Btn1a1 binding proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025510594A true JP2025510594A (ja) 2025-04-15
JP2025510594A5 JP2025510594A5 (enExample) 2026-03-31

Family

ID=88024430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553845A Pending JP2025510594A (ja) 2022-03-16 2023-03-15 Ｂｔｎ１ａ１結合タンパク質及びその使用方法

Country Status (8)

Country Link
US (1) US20250189530A1 (enExample)
EP (1) EP4493594A2 (enExample)
JP (1) JP2025510594A (enExample)
KR (1) KR20240154675A (enExample)
CN (1) CN119213031A (enExample)
AU (1) AU2023236798A1 (enExample)
CA (1) CA3245343A1 (enExample)
WO (1) WO2023178208A2 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071636A (zh) * 2016-03-29 2018-12-21 斯特库比股份有限公司 用于选择特异性结合糖基化免疫检查点蛋白的抗体的方法
GB201909393D0 (en) * 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
KR20220118527A (ko) * 2019-12-23 2022-08-25 제넨테크, 인크. 아포지질단백질 l1-특이적 항체 및 이용 방법

Also Published As

Publication number Publication date
KR20240154675A (ko) 2024-10-25
WO2023178208A3 (en) 2024-03-28
AU2023236798A1 (en) 2024-09-05
CA3245343A1 (en) 2023-09-21
US20250189530A1 (en) 2025-06-12
WO2023178208A2 (en) 2023-09-21
EP4493594A2 (en) 2025-01-22
CN119213031A (zh) 2024-12-27

Similar Documents

Publication Publication Date Title
US20230272076A1 (en) PD-1 Binding Proteins and Methods of Use Thereof
US12084499B2 (en) SIRP-α binding proteins and methods of use thereof
US11292837B2 (en) Nectin-4 binding proteins and methods of use thereof
EP3097122B1 (en) Antibodies binding beta klotho domain 2 and methods of use thereof
US10766958B2 (en) Methods of treating vitiligo using PD-1 binding antibodies
CA3055984A1 (en) Formulations comprising pd-1 binding proteins and methods of making thereof
US11591390B2 (en) SIRP-α binding proteins and methods of use thereof
US20210380675A1 (en) Il-36 antibodies and uses thereof
US20250189530A1 (en) Btn1a1 binding proteins and methods of use thereof
HK40037283A (en) Nectin-4 binding proteins and methods of use thereof
HK40036377A (en) Antibodies binding beta klotho domain 2 and methods of use thereof
HK40026608A (en) Nectin-4 binding proteins and methods of use thereof

Legal Events

Date Code Title Description
RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260318